POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management

Abstract

In England, NICE clinical guidelines on acute management of migraine recommend first-line use of an oral triptan, followed by a non-oral triptan if first-line treatment is ineffective or not tolerated.[1] NHS formularies further suggest trial of tablet formulations before orodispersible tablets and oral lyophilisates.[2-3] New acute therapies with novel mechanisms of action may offer relief for patients who progress beyond first-line triptan tablets.[4] This study aimed to assess the size of this patient population, using recent triptan prescription data for England.